Authors : Ishan P Shah*, Manish Pandya, Bhamini Kadikar, Pankaj Nimbalkar, Tejas Patel
DOI : 10.18231/j.ijogr.2023.026
Volume : 10
Issue : 2
Year : 2023
Page No : 110-114
Background: Anaemia during pregnancy is allied with maternal and foetal complications like increased risk of intrauterine growth retardation, prematurity, low birth weight, and maternal and infant mortality. The agent iron isomaltose 1000 (Fur-IV) combines iron and isomaltose 1000 for slow, controlled release to reduce the risk of free iron toxicity and provide flexibility and convenience for high dose administration. Iron isomaltoside has been shown to be effective in the treatment of IDA in many treatment groups compared to intravenous iron sucrose and FCM.
Materials and Methods: It is a prospective interventional study which is conducted to observe an increase in hemoglobin levels in obstetric and gynecological department patients suffering from IDA in whom oral iron preparation was ineffective or in case of clinical need to supply iron rapidly via single infusion of iron isomaltoside 1000. Each patient in the study received 500 mg single intravenous infusion. After this, patient was followed up and haemogram was repeated after 15 and 30 days of infusion while investigation for serum ferritin and serum iron was repeated after 30 days.
Average Hb concentration in increased by 30.86% to 9.88 g/dL after 30 days of infusion. There is statistically significant difference between baseline values and post infusion 30 days values for serum ferritin and serum iron (p-value <0>
Conclusion: IV iron isomaltoside administration was well tolerated in patients with gynecological IDA who were intolerant or unresponsive to oral iron therapy or who required rapid iron administration.
Keywords: Iron deficiency anemia, Iron isomaltoside.